ConductScience.org, home

Trial · NCT06409702

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

NCT06409702, Phase 4, Recruiting, The First Affiliated Hospital of Soochow University

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection. Trials, record NCT06409702. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06409702

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
NCT number
NCT06409702
Status
Recruiting
Phases
Phase 4
Enrollment
59 participants, estimated
Lead sponsor
The First Affiliated Hospital of Soochow University
Conditions
Newly Diagnosed, High Risk, MRD, Multiple Myeloma
Interventions
Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone, VRD for first-cycle induction therapy
First posted
2024-05-10
Last updated
2025-06-12

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryMRD negative rateCompletion of consolidation therapythe rate of minimal residual disease negativity
Secondary≥VGPR rateafter completion of induction therapy (about 4 months after enrollment) and consolidation therapy(about 11 months after enrollment) , respectivelythe rate of very good partial response or better
Secondaryoverall response rateafter completion of induction therapy (about 4 months after enrollment) and consolidation therapy(about 11 months after enrollment) , respectivelythe rate pf overall response
Secondaryadverse eventsfrom enrollment to completion of following up, about 2 yearsthe rate of adverse events and grade of adverse events
SecondaryPFSfrom enrollment to completion of one-year maintenance therapyProgression-free survival
SecondaryOSfrom enrollment to completion of one-year maintenance therapyoverall survival

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT06409702

GET https://conductscience.org/api/trials/v1/NCT06409702/registered